WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 16, 243-268. Review Article ISSN 2277–7105

QUANTUM DOTS IN PHARMACEUTICAL SCIENCES: BEYOND IMAGING TOWARD ADVANCED DRUG DELIVERY AND PRECISION THERAPEUTICS

[1]*Mr. Pratik Dilip Kachare, [2]Mr. Rohan D. Kachare, [3]Ms. Aakanksha Mane, [4]Ms. Neha Mahanawar, [5]Mrs. Anuradha Salunkhe

Satara College of Pharmacy, Satara, Maharashtra, India.

Article Received on 15 July 2026,
Article Revised on 04 August 2026,
Article Published on 16 August 2026,

https://doi.org/10.5281/zenodo.21913400

***Corresponding Author**

Mr. Pratik Dilip Kachare

Satara College of Pharmacy, Satara, Maharashtra, India.

How to cite this Article: [1]*Mr. Pratik Dilip Kachare, [2]Mr. Rohan D. Kachare, [3]Ms. Aakanksha Mane, [4]Ms. Neha Mahanawar, [5]Mrs. Anuradha Salunkhe. (2026). Quantum Dots In Pharmaceutical Sciences: Beyond Imaging Toward Advanced Drug Delivery And Precision Therapeutics. World Journal of Pharmaceutical Research, 15(16), 243–268.

ABSTRACT

Quantum dots (QDs) are nanoscale semiconductor materials that possess unique size-dependent optical and electronic properties arising from the quantum confinement effect. Initially developed as fluorescent probes for bioimaging, quantum dots have rapidly evolved into multifunctional nanoplatforms with diverse applications in pharmaceutical sciences. Their use in targeted drug delivery, controlled drug release, biosensing, theranostics, gene delivery, vaccine development, antimicrobial therapy, tissue engineering, and precision medicine has been made possible by their remarkable photostability, tunable emission spectra, high surface-area-to-volume ratio, and ease of surface functionalization. Recent advances in carbon- and graphene-based quantum dots have further addressed concerns associated with the toxicity of conventional heavy metal-containing quantum dots, thereby improving their biocompatibility and expanding their biomedical potential. This review provides a comprehensive overview of the fundamental principles, classification, synthesis methods, and characterization techniques of quantum dots, followed by an in-depth discussion of their emerging pharmaceutical applications beyond conventional imaging. Particular emphasis is placed on recent developments in multifunctional drug delivery systems, stimuli-responsive nanocarriers, cancer therapeutics, biosensors, and personalized medicine. Furthermore, the review critically examines the challenges associated with toxicity,

large-scale manufacturing, regulatory approval, and clinical translation. Emerging trends, including green synthesis, artificial intelligence-assisted quantum dot design, and multifunctional nanomedicine, are also highlighted as promising directions for future research. Overall, quantum dots represent a rapidly advancing class of nanomaterials with the potential to transform modern pharmaceutical research and therapeutic strategies, although continued efforts to improve their safety, scalability, and regulatory acceptance remain essential for successful clinical implementation.

KEYWORDS: Quantum dots; Nanomedicine; Targeted drug delivery; Theranostics; Precision medicine; Carbon quantum dots; Biosensors; Drug delivery systems.

1. INTRODUCTION

Nanotechnology has significantly transformed pharmaceutical sciences by providing innovative solutions to overcome the limitations of conventional drug delivery systems, including poor solubility, low bioavailability, and non-specific biodistribution.[1] These nanoscale devices have improved treatment outcomes for a variety of diseases by enabling targeted delivery, regulated drug release, and increased therapeutic efficiency.[2]

Due to their nanoscale dimensions, nanomaterials have special physicochemical characteristics like high surface-area-to-volume ratios, quantum effects, and variable surface chemistry that enable powerful interactions with biological systems.[3] Given these qualities, they are widely used in biomedical engineering, drug delivery, and diagnostics. Quantum dots (QDs) are semiconductor nanocrystals that have drawn a lot of interest among other nanomaterials because of their special optical and electrical characteristics. They differ from traditional organic dyes due to their size-dependent fluorescence emission, high brightness, and photostability, which make them ideal for biomedical applications.[4]

Quantum dots typically range from 2–10 nm in size and exhibit quantum confinement effects, where electronic properties change as a function of particle size. (5) Quantum dots are perfect for multiplex imaging and molecular diagnostics because of this feature, which allows for tunable emission wavelengths. Quantum dots have wider excitation spectra, narrower emission peaks, and better photobleaching resistance than conventional fluorescent dyes. These benefits enable highly sensitive biological target detection, real-time tracking, and long-term imaging.[6]

Initially, quantum dots were primarily used for bioimaging applications such as cellular labelling and tumor visualization.[7] Significant advancements in molecular diagnostics and biological imaging were made possible by their remarkable optical qualities. Quantum dots can now be used for purposes other than imaging thanks to recent developments in surface functionalization. Their usage in targeted drug administration, biosensing, and theranostic applications has been made possible by functionalization with ligands like antibodies, peptides, and polymers.[8]



Figure 1: Evolution of quantum dots in pharmaceutical sciences.

Carbon quantum dots and graphene quantum dots have also emerged as safer alternatives due to reduced heavy metal toxicity and improved biocompatibility.[9] These materials have a great deal of promise for use in pharmaceutical applications, such as antibacterial treatment and drug delivery. Notwithstanding these benefits, toxicity, long-term stability, and clinical translation continue to be significant obstacles. In order to maximize safety and enhance regulatory approval processes, further research is necessary.[10]

All things considered, quantum dots are a promising class of nanomaterials with substantial potential in pharmaceutical sciences other than imaging, especially in precision medicine, drug transport, and diagnostics.[11]

2. Quantum Dots: Structure and Basic Properties

Nanoscale semiconductor particles known as quantum dots (QDs) are usually between 2 and

10 nm in size. When the particle size drops below the exciton Bohr radius, quantum confinement takes place, giving rise to their distinct structure and behaviour. Size-dependent optical and electrical features emerge from discrete energy levels instead than continuous bands.[12]

Semiconductor materials like indium phosphide (InP), cadmium sulfide (CdS), or cadmium selenide (CdSe) typically make up the core of quantum dots. To increase stability, decrease toxicity, and boost fluorescence efficiency, these cores are frequently covered with a shell material like zinc sulfide (ZnS).[13]

The biological performance of quantum dots is significantly influenced by surface modification. Carboxyl, amine, and thiol groups are examples of functional groups that make conjugation with medications, proteins, antibodies, and targeted ligands simple. Because of this, quantum dots are ideal for use in pharmacological and biological applications.[14]

Size-tunable fluorescence emission, excellent photostability, broad absorption with narrow emission spectra, high quantum yield, and readily changeable surfaces for drug loading and targeting are just a few of the significant characteristics of quantum dots. Because of these combined characteristics, quantum dots are superior to traditional fluorescent probes and are very helpful in theranostic, drug administration, and imaging applications.[15]

3. Classification of Quantum Dots

Quantum dots (QDs) can be classified based on their composition and structural design. This classification is important because their biological behavior, toxicity, and pharmaceutical applications strongly depend on their type.

3.1 Classification Based on Composition

(a) Metal-based Quantum Dots

Cadmium selenide (CdSe), cadmium sulfide (CdS), and cadmium telluride (CdTe) are semiconductor materials that make up the majority of metal-based quantum dots. These QDs have strong fluorescence, great brightness, and outstanding optical qualities. However, their clinical applicability is limited due to probable toxicity caused by heavy metal concentration.[16]

(b) Carbon Quantum Dots (CQDs)

Carbon-based nanomaterials with low toxicity and outstanding biocompatibility are known as

carbon quantum dots. They are ideal for biological applications like medication administration, bioimaging, and biosensing since they are environmentally benign and water-soluble.[17]

(c) Graphene Quantum Dots (GQDs)

Graphene sheets are the source of graphene quantum dots, which have special optical and electrical characteristics. In comparison to metal-based quantum dots, they have intense fluorescence, good solubility, great stability, and comparatively low toxicity.[18]

3.2 Classification Based on Structure

(a) Core Quantum Dots

These consist only of a semiconductor core. They show strong fluorescence but are less stable and more prone to surface oxidation.

(b) Core–Shell Quantum Dots

In this type, a shell typically composed of zinc sulfide, or ZnS is applied to the semiconductor core. This structure lessens toxicity, increases fluorescence efficiency, and improves stability.[19]

(c) Doped Quantum Dots

Impurity atoms are incorporated into the crystal structure of doped quantum dots. This alteration aids in adjusting optical characteristics and enhancing fluorescence behavior for particular uses.[20]

4. Physicochemical Properties of Quantum Dots

The distinct physicochemical characteristics of quantum dots (QDs) set them apart from traditional nanomaterials. The quantum confinement effect and their nanoscale dimensions are the main causes of these characteristics, which have a big impact on their optical, electrical, and biological activity. The usefulness of QDs for a range of pharmaceutical applications, such as drug delivery, bioimaging, biosensing, and theranostics, is determined by their physicochemical properties.[21]

Quantum dots' high surface-area-to-volume ratio and small particle size typically between 2 and 10 nm allow for effective drug loading and simple surface modification. They are appealing carriers for targeted drug administration because of their nanoscale size, which also promotes cellular absorption and penetration into biological tissues.[22]



Figure 2: Classification of Quantum Dots.

4.1 Optical Properties

The size-dependent fluorescence emission caused by the quantum confinement effect is one of the most amazing characteristics of quantum dots. Larger quantum dots emit light at longer wavelengths (red region), while smaller quantum dots emit light at shorter wavelengths (blue region). They are very helpful for multiplex imaging and biosensing applications because of their broad absorption spectra and narrow emission peaks, which allow numerous quantum dots to be excited simultaneously using a single light source.[23]

When compared to traditional organic fluorescent dyes, quantum dots also show remarkable photostability. Long-term biological process monitoring and continuous imaging are made possible by their resistance to photobleaching under sustained light. Additionally, its high quantum yield produces strong fluorescent signals that enhance analytical performance and imaging sensitivity.[24]

4.2 Electronic Properties

When compared to traditional organic fluorescent dyes, quantum dots also show remarkable photostability. Long-term biological process monitoring and continuous imaging are made possible by their resistance to photobleaching under sustained light. Additionally, its high quantum yield produces strong fluorescent signals that enhance analytical performance and imaging sensitivity.[25]

As particle size reduces, quantum dots' band gap energy increases, allowing for adjustable optical emission at a variety of wavelengths. Because of these electrical properties, quantum dots can be used in semiconductor-based biomedical applications, biosensors, photovoltaic devices, and fluorescence imaging.[25]

4.3 Surface Charge and Colloidal Stability

The stability and biological performance of quantum dots are strongly influenced by surface charge. Because of their electrostatic interactions with negatively charged cell membranes, positively charged quantum dots typically show increased cellular uptake. They might, however, also result in increased cytotoxicity. On the other hand, neutral or slightly negatively charged quantum dots typically exhibit less nonspecific interactions with proteins and healthy tissues, as well as improved biocompatibility.[26]

Another essential characteristic for medicinal formulations is colloidal stability. In biological fluids, stable quantum dots stay evenly distributed, avoiding aggregation that can negatively impact biodistribution, therapeutic efficacy, and drug delivery efficiency. Colloidal stability is further improved under physiological conditions by surface functionalization with hydrophilic polymers.[26]

4.4 Importance of Physicochemical Properties in Pharmaceutical Applications

Quantum dots' pharmacokinetic behavior, targeting effectiveness, drug-loading capacity, and imaging capability are all influenced by their physicochemical characteristics. Researchers can create multifunctional quantum dots for targeted drug administration, molecular diagnostics, theranostics, and precision medicine by carefully regulating particle size, surface chemistry, fluorescence properties, and colloidal stability.[26]

5. Surface Functionalization of Quantum Dots

One of the most crucial methods for enhancing quantum dots' pharmacological performance is surface functionalization. Surface modification is necessary to increase water solubility, stability, biocompatibility, and targeting ability since newly synthesized quantum dots frequently have hydrophobic surfaces and low biological compatibility. Additionally, functionalization makes it possible to attach therapeutic drugs and targeting molecules, which broadens the range of biomedical uses for quantum dots.[27]

Functional groups including carboxyl (-COOH), amine (-NH_2), hydroxyl (-OH), and thiol (-

SH) are added to the surface of quantum dots through surface modification. These groups provide active sites for conjugating medicines, proteins, antibodies, nucleic acids, peptides, and polymers through covalent or non-covalent interactions.[28]

5.1 Polymer Functionalization

Quantum dots are frequently functionalized using hydrophilic polymers including polyethylene glycol (PEG), polyethyleneimine (PEI), chitosan, and polyvinyl alcohol (PVA). Polymer coating lessens immune system recognition, increases aqueous dispersibility, decreases particle aggregation, and lengthens blood circulation time. In particular, PEGylation has gained popularity as a method for improving the pharmacokinetic characteristics of nanocarriers.[29]

5.2 Ligand Conjugation

Biological ligands like antibodies, peptides, aptamers, folic acid, and transferrin can be coupled with quantum dots. These ligands enable the selective accumulation of quantum dots at the target region by identifying particular receptors that are overexpressed on sick cells. While reducing off-target toxicity, ligand-mediated targeting greatly increases therapeutic efficacy.[30]

5.3 Drug and Biomolecule Conjugation

The functionalized surface of quantum dots permits efficient attachment of numerous therapeutic molecules, including anticancer medicines, antibiotics, genes, proteins, and small interfering RNA (siRNA). Depending on the physicochemical properties of the drug and the quantum dot surface, drug conjugation can take place via covalent bonds, electrostatic interactions, or physical adsorption. Controlled drug release can further be achieved by creating stimuli-responsive linkers that respond to pH, enzymes, temperature, or light.[30]

5.4 Advantages of Surface Functionalization

By boosting water solubility, improving colloidal stability, lowering toxicity, and enabling active targeting, surface functionalization significantly increases the medicinal usefulness of quantum dots. By integrating therapeutic and diagnostic capabilities into a single nanoplatform, it also promotes extended circulation, effective drug loading, enhanced cellular uptake, and multifunctionality. Surface-functionalized quantum dots are now excellent options for enhanced drug delivery, biosensing, theranostics, and precision medicine because of these benefits.[30]

6. Synthesis of Quantum Dots

Numerous physical, chemical, and biological methods can be used to create quantum dots (QDs). Quantum dots' size, shape, crystallinity, optical qualities, and surface features are all determined by the synthesis process and ultimately affect how well they work as medicines. For the production of highly fluorescent, stable, and biocompatible QDs appropriate for drug delivery, bioimaging, biosensing, and theranostic applications, appropriate synthesis procedures are crucial.[31]



Figure 3: Synthesis of Quantum Dots.

6.1 Top-Down Methods

Top-down methods use physical production processes to reduce bulk semiconductor materials to nanoscale particles. Laser ablation, mechanical milling, photolithography, electron beam lithography, and chemical etching are examples of common techniques. These approaches provide good control over particle dimensions and are appropriate for creating semiconductor nanostructures with predetermined geometries. But top-down approaches frequently produce surface flaws and structural flaws that can lower quantum yield and fluorescence efficiency. In addition, these approaches often need complex apparatus and are less inexpensive for large-scale production, limiting potential pharmaceutical uses.[31]

6.2 Bottom-Up Methods

Chemical reactions are used in bottom-up synthesis to carefully assemble atoms or molecular precursors into tiny quantum dots. Colloidal synthesis, sol–gel synthesis, hydrothermal and solvothermal procedures, chemical vapor deposition (CVD), and microwave-assisted synthesis are frequently used methods. Because it offers superior control over particle size, morphology, crystal quality, and fluorescence qualities, colloidal synthesis is the most popular of these techniques. Because bottom-up methods typically provide extremely crystalline quantum dots with exceptional optical properties and a limited size distribution, they are especially well-suited for biomedical and pharmacological applications.[32]

6.3 Green Synthesis

An eco-friendly substitute for traditional chemical processes is green synthesis. As reducing and stabilizing agents during quantum dot creation, it makes use of renewable biological resources such bacteria, fungi, algae, plant extracts, and natural polymers. This strategy decreases production costs, minimizes the use of dangerous chemicals, and lessens pollution in the environment. Green-synthesised quantum dots, especially carbon quantum dots, are intriguing options for drug delivery, bioimaging, biosensing, and antimicrobial applications due to their increased water stability, decreased cytotoxicity, and improved biocompatibility.[33]

6.4 Surface Functionalization

A crucial post-synthesis alteration that enhances the physicochemical and biological characteristics of quantum dots is surface functionalization. Functional groups like carboxyl (-COOH), amine ($-NH_2$), hydroxyl (-OH), and thiol (-SH) provide active sites for biomolecule conjugation and improve water solubility, colloidal stability, and biocompatibility. To accomplish targeted drug delivery and regulated drug release, surface-functionalized quantum dots can be coupled with antibodies, peptides, aptamers, polymers, nucleic acids, and medicinal medicines. Additionally, functionalization increases the clinical potential of quantum dot-based nanomedicines by reducing nonspecific interactions, minimizing toxicity, and extending blood circulation.[34]

7. Characterization Techniques of Quantum Dots

To ascertain the physicochemical, structural, morphological, and optical characteristics of quantum dots (QDs), characterization is crucial. Particle size, shape, crystallinity, surface chemistry, fluorescence behavior, and colloidal stability are all assessed using a variety of

analytical methods. Thorough characterisation guarantees that the synthesis was effective and that quantum dots are appropriate for use in pharmaceutical applications such drug transport, bioimaging, biosensing, and theranostics.[35]

7.1 Transmission Electron Microscopy (TEM)

One of the most crucial methods for characterizing quantum dots is transmission electron microscopy (TEM). It offers high-resolution pictures that show the size distribution, crystal structure, shape, and size of particles at the nanoscale. Additionally, TEM verifies the proper production of monodispersed quantum dots, which is crucial for consistent pharmacological performance, and assists in determining particle homogeneity.[35]

7.2 Scanning Electron Microscopy (SEM)

Quantum dots' topographical characteristics and surface shape are investigated using scanning electron microscopy (SEM). It offers details on overall structural arrangement, surface roughness, and particle aggregation. By providing a thorough picture of surface properties that affect drug loading and biological interactions, SEM enhances TEM.[35]

7.3 Dynamic Light Scattering (DLS)

The hydrodynamic diameter and particle size distribution of quantum dots distributed in liquid media are frequently measured using dynamic light scattering (DLS). Additionally, it offers important insights into colloidal stability and aggregation behavior in physiological settings. When assessing nanoparticle formulations meant for pharmaceutical and biological uses, DLS is very crucial.[36]

7.4 X-Ray Diffraction (XRD)

Quantum dot crystallinity, phase purity, and crystalline structure are all determined using X-ray diffraction (XRD). In addition to providing details about the average crystallite size and crystal lattice properties, the diffraction pattern verifies the successful formation of nanocrystals. XRD analysis is critical for confirming the structural integrity and quality of produced quantum dots.[35]

7.5 Fourier Transform Infrared Spectroscopy (FTIR)

Functional groups on the surface of quantum dots are identified using Fourier Transform Infrared Spectroscopy (FTIR). By identifying distinctive vibrational frequencies of chemical bonds, it verifies surface modification, ligand attachment, and effective conjugation of

medications or biomolecules. Thus, FTIR is a crucial instrument for assessing surface functionalization.[37]

7.6 UV–Visible Spectroscopy

The optical absorption properties of quantum dots are studied using UV-visible spectroscopy. It offers data on band-gap energy, electrical transitions, and absorption spectra, all of which are intimately correlated with particle size due to the quantum confinement effect. Quantum dot production and optical behavior are frequently observed using UV-Vis analysis.[38]

7.7 Photoluminescence (PL) Spectroscopy

One important analytical method for assessing the fluorescence characteristics of quantum dots is photoluminescence (PL) spectroscopy. It monitors emission wavelength, fluorescence intensity, emission efficiency, and quantum yield. PL analysis is particularly crucial for analysing the appropriateness of quantum dots for bioimaging, biosensing, and theranostic applications.[39]

7.8 Zeta Potential Analysis

Quantum dots' surface charge is measured by zeta potential analysis, which also reveals details about their colloidal stability in suspension. Higher absolute zeta potential values suggest stronger electrostatic repulsion between particles, hence minimizing aggregation and boosting stability. This metric is essential for forecasting the pharmacological performance, biodistribution, and storage stability of quantum dot formulations.[40]

8. Quantum Dots Beyond Imaging

Due to their exceptional optical characteristics, such as great photostability, wide excitation spectra, narrow emission bands, and size-dependent fluorescence, quantum dots (QDs) were first created as fluorescent probes for biomedical imaging. QDs are now multifunctional nanoplatforms that can be used for both therapeutic and diagnostic purposes thanks to recent developments in surface engineering and nanotechnology. Their applications beyond imaging have been greatly expanded into targeted drug delivery, cancer therapy, gene delivery, biosensing, theranostics, regenerative medicine, and precision therapeutics due to their large surface-area-to-volume ratio, ease of functionalization, and capacity to carry multiple biomolecules at once.[41]

8.1 Targeted Drug Delivery

To accomplish site-specific drug delivery, quantum dots can be coupled with targeting ligands such monoclonal antibodies, peptides, aptamers, folic acid, polysaccharides, and polymers. Through receptor-mediated endocytosis, these ligands selectively identify receptors that are overexpressed on sick cells, including cancer cells, leading to increased cellular absorption. Therapeutic drugs and imaging molecules can be simultaneously attached to QDs' multifunctional surface, limiting off-target toxicity and enabling real-time drug distribution monitoring. These targeted delivery methods increase the effectiveness of treatment, lessen systemic side effects, and are a key tactic in precision medicine.[41]

8.2 Controlled and Stimuli-Responsive Drug Release

Quantum dots have been integrated into stimulus-responsive nanocarriers that can release medications in response to certain internal or external stimuli, including light irradiation, pH, temperature, redox potential, enzymes, and magnetic fields. Drug bioavailability is increased and premature drug leakage is reduced because to this regulated release. For instance, pH-sensitive drug release from QD-based nanocarriers can be triggered by acidic tumor microenvironments or intracellular lysosomes, while light-responsive devices enable temporal and geographic control over therapeutic delivery. These intelligent delivery methods improve the accuracy of treatment and lessen harm to healthy tissues.[42]

8.3 Cancer Therapy

Cancer therapy represents one of the most extensively investigated pharmaceutical applications of quantum dots. QDs serve as multifunctional nanocarriers capable of delivering chemotherapeutic drugs directly to tumor tissues while simultaneously providing fluorescent imaging for monitoring therapeutic response. In addition to targeted chemotherapy, quantum dots have shown significant potential in photodynamic therapy (PDT) and photothermal therapy (PTT), where they generate reactive oxygen species or localized heat upon light irradiation, leading to selective destruction of cancer cells. Their multifunctional nature supports personalized cancer treatment by integrating diagnosis, targeted therapy, and treatment monitoring within a single nanosystem.[43]

8.4 Gene and Nucleic Acid Delivery

Quantum dots have emerged as promising carriers for gene therapy because they can efficiently transport DNA, messenger RNA (mRNA), small interfering RNA (siRNA), microRNA (miRNA), and CRISPR-associated nucleic acids into target cells. Surface

modification increases intracellular transport efficiency and shields nucleic acids from enzyme destruction. Additionally, QDs' inherent fluorescence makes it possible to see intracellular gene trafficking and cellular uptake in real time, which makes it easier to monitor gene expression and treatment results. Because of these characteristics, QDs are useful treatments for infectious illnesses, cancer, and genetic abnormalities.[44]

8.5 Antimicrobial Applications

Through a variety of methods, such as the production of reactive oxygen species (ROS), rupture of bacterial cell membranes, interference with DNA replication, and blockage of vital metabolic pathways, quantum dots demonstrate inherent antimicrobial activity. When compared to traditional antibiotics, these processes lessen the possibility of microbial resistance. Carbon and graphene quantum dots are attractive options for wound healing, antimicrobial coatings, and the treatment of drug-resistant infections since they have shown strong antibacterial action against a variety of Gram-positive and Gram-negative bacteria as well as fungal diseases.[45]

8.6 Vaccine Delivery

Quantum dots are being studied more and more as innovative immunomodulatory platforms and vaccine delivery systems. Their nanoscale size makes it easier for adjuvants and antigens to be transported to antigen-presenting cells, which improves antigen presentation and immune activation. QD-based vaccination formulations have shown increased humoral and cellular immune responses, longer circulation times, and greater antigen stability. They are appealing candidates for next-generation vaccinations against cancer and infectious illnesses because of these qualities.[46]

8.7 Biosensors and Diagnostics

Quantum dots' remarkable optical characteristics make them ideal for biosensing applications. Highly sensitive and multiplex detection of biomarkers, proteins, nucleic acids, enzymes, toxins, and pathogens is made possible by their intense fluorescence, high quantum yield, and narrow emission spectra. Compared to many traditional analytical techniques, quantum dot-based biosensors offer quick, precise, and extremely sensitive detection with reduced detection limits. These systems are being investigated more and more for personalized healthcare, point-of-care diagnostics, and early illness identification.[47]

8.8 Theranostics

Theranostics integrates therapeutic intervention and diagnostic imaging into a single nanosystem. Because quantum dots may serve as both drug delivery vehicles and imaging probes at the same time, they are especially well suited for theranostic applications. Clinicians can examine drug distribution, track therapy response in real time, and improve dosing techniques by combining medicinal drugs with fluorescent quantum dots. This dual feature reduces needless medication exposure, greatly enhances treatment accuracy, and enables individualized therapy.[48]

8.9 Brain Drug Delivery

The blood brain barrier (BBB), which limits drug transport into the central nervous system, is one of the biggest obstacles to treating neurological disorders. Functionalized quantum dots have shown the ability to traverse the BBB through receptor-mediated transport processes, enabling targeted brain medication delivery. The delivery of therapeutic drugs to treat Alzheimer's disease, Parkinson's disease, glioblastoma, epilepsy, and other neurological disorders is being studied using quantum dot-based nanocarriers. Drug localization inside brain tissues can also be monitored thanks to their simultaneous imaging capacity.[49]

8.10 Tissue Engineering and Regenerative Medicine

Quantum dots have gained increasing attention in tissue engineering because of their excellent fluorescence stability and long-term cellular tracking capability. They are frequently used for cell movement research, stem cell labelling, scaffold imaging, and tissue regeneration process monitoring. Non-invasive monitoring of tissue growth, cellular differentiation, and scaffold degradation is made possible by the integration of quantum dots into biomaterial scaffolds. These applications enhance knowledge of tissue regeneration mechanisms and aid in the development of sophisticated regenerative therapeutics.[50]



Figure 4: Pharmaceutical applications of quantum dots beyond imaging in pharmaceutical sciences.

9. Toxicity and Biocompatibility of Quantum Dots

Quantum dots (QDs) have a lot of potential in drug delivery, bioimaging, biosensing, and theranostic applications, but their clinical translation is still difficult because of issues with toxicity and long-term biocompatibility. The toxicity of QDs varies on various aspects, including their chemical composition, particle size, surface charge, coating materials, dose, mode of administration, and duration of exposure. Under physiological conditions, heavy metal-containing QDs, especially cadmium-based nanocrystals, may emit toxic metal ions, which could have negative biological impacts. Therefore, understanding the toxicity processes and designing safer quantum dots are vital for their successful medicinal application.[51]

9.1 Sources of Toxicity

The main cause of quantum dots' toxicity is the breakdown of semiconductor cores, which releases hazardous heavy metal ions as tellurium (Te^{2-}), cadmium (Cd^{2+}), and selenium (Se^{2-}). These ions can cause oxidative stress, mitochondrial malfunction, inflammation, and apoptosis in addition to interfering with regular cellular metabolism. The production of reactive oxygen species (ROS), which oxidatively damages proteins, lipids, nucleic acids, and cellular membranes, is another crucial mechanism. The biological use of some QDs may

be limited by excessive ROS generation, which can cause DNA damage, genomic instability, and cell death.[51]

9.2 Heavy Metal-Based Quantum Dots

While cadmium-based quantum dots, such as cadmium telluride (CdTe), cadmium selenide (CdSe), and cadmium sulfide (CdS), have good fluorescence characteristics, metal ion leakage during degradation raises serious safety issues. Higher concentrations, extended exposure, and insufficient surface protection all increase their toxicity. Experimental investigations have indicated that these nanoparticles can aggregate in organs like the liver, kidneys, spleen, lungs, and brain, potentially causing organ dysfunction, inflammatory responses, and compromised physiological activities. Consequently, their direct clinical applicability remains limited despite their excellent optical performance.[52]

9.3 Carbon and Graphene Quantum Dots

Due to their superior biocompatibility, low cytotoxicity, high water solubility, and environmental friendliness, carbon quantum dots (CQDs) and graphene quantum dots (GQDs) have become attractive substitutes for traditional semiconductor QDs. These nanostructures typically don't include hazardous heavy metals because they are made from carbon-rich precursors. CQDs and GQDs have good fluorescence properties, chemical stability, and easy surface modification in addition to their positive safety profile. They are appealing options for drug administration, bioimaging, biosensing, antimicrobial therapy, and tissue engineering applications due to their quick renal clearance and decreased accumulation in important organs.[53]

9.4 Strategies to Reduce Toxicity

A number of methods have been explored to enhance quantum dots' safety profile. Chemical stability is improved and harmful metal ion leakage is efficiently stopped by surface coating with zinc sulfide (ZnS), silica, polyethylene glycol (PEG), phospholipids, and biocompatible polymers. Surface functionalization with polymers, peptides, carbohydrates, or antibodies increases target specificity, prolongs blood circulation, decreases immune recognition, and improves water solubility. Systemic toxicity is greatly decreased and direct interaction with biological tissues is minimized when QDs are encapsulated in liposomes, polymeric nanoparticles, or biodegradable nanocarriers.[54]

9.5 Biocompatibility Considerations

Quantum dots' particle size, morphology, surface charge, surface chemistry, and biodegradability all have a significant impact on their biocompatibility. In general, smaller nanoparticles have higher cellular absorption; but, if improperly constructed, they may also show increased intracellular accumulation and toxicity. Surface charge affects how biological membranes, immune cells, and plasma proteins interact. When compared to extremely positively charged nanoparticles, neutral or slightly negatively charged QDs often show better biological compatibility, less nonspecific protein adsorption, and longer circulation. For pharmaceutical applications, appropriate surface functionalization and biodegradable coatings significantly increase stability, decrease immunogenicity, and improve overall safety of QDs.[55]

10. Regulatory and Manufacturing Challenges

Despite the tremendous advances in the creation of quantum dots (QDs) for pharmaceutical and biomedical applications, their successful clinical translation remains limited due to many manufacturing, quality control, regulatory, and commercialization obstacles. The clearance of QD-based nanomedicines has been hindered by the intricacy of quantum dot synthesis, worries about long-term safety, and the lack of uniform regulatory requirements. Addressing these problems is critical to assure the safe, reproducible, and cost-effective manufacture of quantum dots for clinical usage.[56]

10.1 Scale-Up Production

Large-scale production while preserving constant physicochemical features is one of the biggest obstacles to the commercialization of quantum dots. Strict control over particle size, morphology, crystal structure, fluorescence properties, and surface chemistry is necessary for industrial production. The biological performance, biodistribution, and therapeutic efficacy of quantum dots can be greatly impacted by even little changes made during synthesis. Large-scale production is also costly and environmentally difficult because many traditional synthesis techniques call for high temperatures, hazardous solvents, and difficult purification processes. Therefore, industrial manufacturing requires the development of scalable, repeatable, and environmentally benign synthesis techniques.[56]

10.2 Quality Control and Standardization

For quantum dot compositions to be safe, effective, and repeatable, quality control is crucial. Pharmaceutical performance and clinical results can be greatly impacted by batch-to-batch

differences in particle size, size distribution, surface functionalization, fluorescence intensity, and colloidal stability. Establishing product consistency requires thorough characterization utilizing analytical methods like TEM, DLS, XRD, FTIR, UV–visible spectroscopy, photoluminescence spectroscopy, and zeta potential studies. Commercial production and regulatory approval depend on standardized manufacturing procedures and globally recognized quality standards.[57]

10.3 Regulatory Challenges

Because current pharmaceutical rules were primarily created for conventional pharmaceuticals rather than nanomaterials, obtaining regulatory approval for quantum dot-based treatments continues to be a major challenge. The regulatory approval of quantum dot-based therapeutics remains a significant obstacle because existing pharmaceutical regulations were primarily developed for conventional drugs rather than nanomaterials. Currently, there is no universally accepted regulatory framework specifically designed for evaluating the safety, efficacy, pharmacokinetics, and environmental impact of quantum dots. Heavy metal-containing quantum dots receive additional regulatory scrutiny because of concerns regarding long-term toxicity, biodegradation, and environmental accumulation. Regulatory agencies require comprehensive preclinical evaluation, including toxicity studies, biodistribution, pharmacokinetics, immunogenicity, genotoxicity, and long-term safety assessments before clinical approval.[58]

10.4 Clinical Translation

Only a small number of formulations have advanced to clinical review, despite the fact that thousands of research studies have shown the promise of quantum dots in laboratory settings. Concerns about toxicity, a lack of long-term safety data, manufacturing complexity, high production costs, and challenges in producing repeatable large-scale synthesis are some of the main obstacles. Furthermore, the extensive clinical use of quantum dots is still hampered by our incomplete knowledge of their long-term biodistribution, metabolism, clearance, and environmental impact. To speed up clinical translation, researchers, physicians, regulators, and the pharmaceutical sector must work together.[59]

10.5 Future Perspectives

The development of biodegradable, heavy metal-free quantum dots with enhanced biocompatibility and low toxicity should be the main goal of future research. Reproducibility, scalability, and product quality could be greatly enhanced by green synthesis techniques,

continuous-flow manufacturing, and artificial intelligence-assisted synthesis parameter optimization. The transition of quantum dot technology from laboratory research to normal clinical practice will depend heavily on the development of standardized regulatory guidelines, proven characterization techniques, and production facilities that adhere to Good Manufacturing Practice (GMP). It is anticipated that ongoing interdisciplinary cooperation will make it easier to create pharmaceutical solutions based on quantum dots that are safe, efficient, and profitable.[60]

11. Future Perspectives

The future of quantum dots (QDs) in pharmaceutical sciences lies in the development of safer, biodegradable, and highly biocompatible nanomaterials capable of overcoming the limitations associated with conventional semiconductor quantum dots. Increasing emphasis is being placed on heavy metal-free quantum dots, including carbon quantum dots and graphene quantum dots, owing to their improved biosafety and environmental compatibility. Continued research into green synthesis approaches and sustainable manufacturing technologies is expected to facilitate the production of quantum dots with consistent quality while minimizing environmental impact.[61]

Advances in surface engineering and nanotechnology are expected to enable the design of multifunctional quantum dots with enhanced targeting efficiency, prolonged circulation time, and controlled drug release. The integration of artificial intelligence, machine learning, and computational modelling into nanoparticle design may further optimize particle characteristics, predict biological interactions, and accelerate the development of personalized nanomedicines. In addition, stimuli-responsive quantum dots capable of responding to pH, temperature, enzymes, light, or magnetic fields are anticipated to improve the precision and effectiveness of targeted therapeutic interventions.[62]

Future progress will also depend on establishing standardized manufacturing protocols, comprehensive long-term toxicity studies, and globally harmonized regulatory guidelines. Collaboration among pharmaceutical scientists, material scientists, clinicians, and regulatory agencies will be essential to overcome current challenges and facilitate the successful clinical translation of quantum dot-based drug delivery systems. With continued technological advancements, quantum dots are expected to become an integral component of next-generation pharmaceutical formulations, enabling more precise, efficient, and personalized healthcare solutions.[63]

12. CONCLUSION

Quantum dots have emerged as one of the most promising classes of nanomaterials in pharmaceutical sciences because of their unique size-dependent optical and electronic properties, excellent photostability, high quantum yield, and versatile surface chemistry. Although initially developed as fluorescent probes for bioimaging, they have evolved into multifunctional nanoplatforms with diverse applications in targeted drug delivery, controlled drug release, cancer therapy, gene delivery, biosensing, theranostics, antimicrobial therapy, vaccine delivery, brain-targeted drug delivery, and tissue engineering. These advances highlight the remarkable potential of quantum dots to integrate diagnostic and therapeutic functions within a single nanosystem, thereby supporting the development of precision medicine.

Recent innovations in carbon quantum dots, graphene quantum dots, and advanced surface functionalization strategies have significantly improved the biocompatibility and pharmaceutical applicability of these nanomaterials. Nevertheless, challenges related to long-term toxicity, large-scale manufacturing, quality control, regulatory approval, and clinical translation continue to limit their widespread clinical use. Addressing these challenges through interdisciplinary research, technological innovation, and robust regulatory frameworks will be essential for realizing the full therapeutic potential of quantum dots.

Overall, quantum dots represent a rapidly advancing and versatile nanotechnology platform with the capacity to transform modern pharmaceutical research and clinical practice. Continued scientific progress and collaborative efforts are expected to pave the way for the successful integration of quantum dot-based systems into future drug delivery strategies, diagnostics, and precision therapeutics.

REFERENCES

1. Allen, T. M., & Cullis, P. R. Drug delivery systems: Entering the mainstream. *Science*, 2004; 303(5665): 1818–1822. https://doi.org/10.1126/science.1095833
2. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. Nanocarriers as emerging platform for cancer therapy. *Nature Nanotechnology*, 2007; 2(12): 751–760. https://doi.org/10.1038/nnano.2007.387
3. Park, K. Nanotechnology: What it can do for drug delivery. *Journal of Controlled Release*, 2014; 190: 3–8. https://doi.org/10.1016/j.jconrel.2014.03.027

4. Alivisatos, A. P. Semiconductor clusters, nanocrystals, and quantum dots. *Science*, 1996; 271(5251): 933–937. https://doi.org/10.1126/science.271.5251.933
5. Brus, L. E. Electron–electron and electron–hole interactions in semiconductor nanocrystals. *Journal of Chemical Physics*, 1984; 80: 4403–4409. https://doi.org/10.1063/1.447218
6. Resch-Genger, U., et al. Quantum dots versus organic dyes. *Nature Methods*, 2008; 5: 763–775. https://doi.org/10.1038/nmeth.1248
7. Michalet, X., et al. Quantum dots for live-cell imaging. *Science*, 2005; 307: 538–544. https://doi.org/10.1126/science.1104274
8. Medintz, I. L., Uyeda, H. T., Goldman, E. R., & Mattoussi, H. Quantum dot bioconjugates. *Nature Materials*, 2005; 4: 435–446. https://doi.org/10.1038/nmat1390
9. Lim, S. Y., Shen, W., & Gao, Z. Carbon quantum dots and their applications. *Chemical Society Reviews*, 2015; 44: 362–381. https://doi.org/10.1039/C4CS00269E
10. Hardman, R. A toxicologic review of quantum dots. *Environmental Health Perspectives*, 2006; 114: 165–172.
11. Bayda, S., Amadio, E., Cailotto, S., Frión-Herrera, Y., Perosa, A., & Rizzolio, F. Carbon dots for cancer nanomedicine: A bright future. *Nanoscale Advances*, 2021; *3:* 5183–5221. https://doi.org/10.1039/D1NA00036E
12. Alivisatos, A. P. The use of nanocrystals in biological detection. *Nature Biotechnology*, 2004; *22*(1): 47–52. https://doi.org/10.1038/nbt1018
13. Resch-Genger, U., Grabolle, M., Cavaliere-Jaricot, S., Nitschke, R., & Nann, T. Quantum dots versus organic dyes as fluorescent labels. *Nature Methods*, 2008; *5*(9): 763–775. https://doi.org/10.1038/nmeth.1248
14. Medintz, I. L., Uyeda, H. T., Goldman, E. R., & Mattoussi, H. Quantum dot bioconjugates for imaging, labelling and sensing. *Nature Materials*, 2005; *4*(6): 435–446. https://doi.org/10.1038/nmat1390
15. Smith, A. M., Duan, H., Mohs, A. M., & Nie, S. Bioconjugated quantum dots for in vivo molecular and cellular imaging. *Advanced Drug Delivery Reviews*, 2008; *60*(11): 1226–1240. https://doi.org/10.1016/j.addr.2008.03.015
16. Kairdolf, B. A., Smith, A. M., Stokes, T. H., & Nie, S. The present and future of quantum dots in biology and medicine. *Annual Review of Analytical Chemistry*, 2013; *6:* 143–162. https://doi.org/10.1146/annurev-anchem-060908-155136
17. Lim, S. Y., Shen, W., & Gao, Z. Carbon quantum dots and their biomedical applications. *Chemical Society Reviews*, 2015; *44*(1): 362–381. https://doi.org/10.1039/C4CS00269E

18. Li, L., Wu, G., Yang, G., Peng, J., & Zhao, J. Focusing on luminescent graphene quantum dots: Current status and future perspectives. *Nanoscale*, 2013; *5*(10): 4015–4039. https://doi.org/10.1039/C3NR33849E
19. Talapin, D. V., Lee, J. S., Kovalenko, M. V., & Shevchenko, E. V. Prospects of colloidal nanocrystals for electronic and optoelectronic applications. *Chemical Reviews*, 2010; *110*(1): 389–458. https://doi.org/10.1021/cr900137k
20. Wang, R., & Wang, X. Doped semiconductor quantum dots: Synthesis and applications. *Materials Science and Engineering: R.*, 2014; *82:* 1–28. https://doi.org/10.1016/j.mser.2014.04.001
21. Murray, C. B., Kagan, C. R., & Bawendi, M. G. Synthesis and characterization of monodisperse nanocrystals and close-packed nanocrystal assemblies. *Annual Review of Materials Science*, 2000; *30:* 545–610. https://doi.org/10.1146/annurev.matsci.30.1.545
22. Alivisatos, A. P. Semiconductor clusters, nanocrystals, and quantum dots. *Science*, 1996; *271*(5251): 933–937. https://doi.org/10.1126/science.271.5251.933
23. Bruchez, M., Moronne, M., Gin, P., Weiss, S., & Alivisatos, A. P. Semiconductor nanocrystals as fluorescent biological labels. *Science*, 1998; *281*(5385): 2013–2016. https://doi.org/10.1126/science.281.5385.2013
24. Smith, A. M., Duan, H., Mohs, A. M., & Nie, S. Bioconjugated quantum dots for in vivo molecular and cellular imaging. *Advanced Drug Delivery Reviews*, 2008; *60*(11): 1226–1240. https://doi.org/10.1016/j.addr.2008.03.015
25. Sze, S. M. (2008). *Semiconductor devices: Physics and technology* (2nd ed.). Wiley.
26. Bhattacharjee, S. DLS and zeta potential—What they are and what they are not? *Journal of Controlled Release*, 2016; *235:* 337–351. https://doi.org/10.1016/j.jconrel.2016.06.017
27. Medintz, I. L., Uyeda, H. T., Goldman, E. R., & Mattoussi, H. Quantum dot bioconjugates for imaging, labelling and sensing. *Nature Materials*, 2005; *4*(6): 435–446. https://doi.org/10.1038/nmat1390
28. Hermanson, G. T. (2013). *Bioconjugate techniques* (3rd ed.). Academic Press.
29. Owens, D. E., III, & Peppas, N. A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. *International Journal of Pharmaceutics*, 2006; *307*(1): 93–102. https://doi.org/10.1016/j.ijpharm.2005.10.010
30. Kairdolf, B. A., Smith, A. M., Stokes, T. H., Wang, M. D., Young, A. N., & Nie, S. Semiconductor quantum dots for bioimaging and biodiagnostic applications. *Annual Review of Analytical Chemistry*, 2013; *6:* 143–162. https://doi.org/10.1146/annurev-anchem-060908-155136

31. Murray, C. B., Norris, D. J., & Bawendi, M. G. Synthesis and characterization of nearly monodisperse CdE (E = S, Se, Te) semiconductor nanocrystallites. *Journal of the American Chemical Society*, 1993; *115*(19): 8706–8715. https://doi.org/10.1021/ja00072a025
32. Kamat, P. V. Quantum dot solar cells: Semiconductor nanocrystals as light harvesters. *The Journal of Physical Chemistry C.*, 2008; *112*(48): 18737–18753. https://doi.org/10.1021/jp806791s
33. Li, H., He, X., Kang, Z., Huang, H., Liu, Y., Liu, J., Lian, S., Tsang, C. H. A., Yang, X., & Lee, S. T. Water-soluble fluorescent carbon quantum dots and photocatalyst design. *Angewandte Chemie International Edition*, 2010; *49*(26): 4430–4434. https://doi.org/10.1002/anie.200906154
34. Medintz, I. L., Uyeda, H. T., Goldman, E. R., & Mattoussi, H. Quantum dot bioconjugates for imaging, labelling and sensing. *Nature Materials*, 2005; *4*(6): 435–446. https://doi.org/10.1038/nmat1390
35. Murray, C. B., Kagan, C. R., & Bawendi, M. G. Synthesis and characterization of monodisperse nanocrystals and close-packed nanocrystal assemblies. *Annual Review of Materials Science*, 2000; *30:* 545–610. https://doi.org/10.1146/annurev.matsci.30.1.545
36. Bhattacharjee, S. DLS and zeta potential—What they are and what they are not? *Journal of Controlled Release*, 2016; *235:* 337–351. https://doi.org/10.1016/j.jconrel.2016.06.017
37. Stuart, B. H. (2004). *Infrared spectroscopy: Fundamentals and applications*. Wiley.
38. Yu, W. W., Qu, L., Guo, W., & Peng, X. Experimental determination of the extinction coefficient of CdTe, CdSe, and CdS nanocrystals. *Chemistry of Materials*, 2003; *15*(14): 2854–2860. https://doi.org/10.1021/cm034081k
39. Lakowicz, J. R. (2006). *Principles of fluorescence spectroscopy* (3rd ed.). Springer.
40. Sze, S. M. (2008). *Semiconductor devices: Physics and technology* (3rd ed.). Wiley.
41. Medintz, I. L., Uyeda, H. T., Goldman, E. R., & Mattoussi, H. *Quantum dot bioconjugates for imaging, labeling, and sensing*. Nature Materials, 2005; 4(6): 435–446. https://doi.org/10.1038/nmat1390
42. Mura, S., Nicolas, J., & Couvreur, P. *Stimuli-responsive nanocarriers for drug delivery*. Nature Materials, 2013; 12(11): 991–1003. https://doi.org/10.1038/nmat3776
43. Smith, A. M., Duan, H., Mohs, A. M., & Nie, S. *Bioconjugated quantum dots for in vivo molecular and cellular imaging*. Advanced Drug Delivery Reviews, 2008; 60(11): 1226–1240. https://doi.org/10.1016/j.addr.2008.03.015

44. Gao, X., Yang, L., Petros, J. A., Marshall, F. F., Simons, J. W., & Nie, S. *In vivo molecular and cellular imaging with quantum dots*. Current Opinion in Biotechnology, 2005; 16(1): 63–72. https://doi.org/10.1016/j.copbio.2004.12.002
45. Li, L., Wu, G., Yang, G., Peng, J., Zhao, J., & Zhu, J. J. *Focusing on luminescent graphene quantum dots: Current status and future perspectives*. Nanoscale, 2013; 5(10): 4015–4039. https://doi.org/10.1039/C3NR33849E
46. Li, L., Wu, G., Yang, G., Peng, J., Zhao, J., & Zhu, J. J. *Focusing on luminescent graphene quantum dots: Current status and future perspectives*. Nanoscale, 2013; 5(10): 4015–4039. https://doi.org/10.1039/C3NR33849E
47. Lakowicz, J. R. (2006). *Principles of fluorescence spectroscopy* (3rd ed.). Springer.
48. Smith, A. M., Rhyner, M. N., & Nie, S. *Semiconductor quantum dots for bioimaging*. Accounts of Chemical Research, 2009; 42(5): 543–553. https://doi.org/10.1021/ar8001922
49. Gao, X., Cui, Y., Levenson, R. M., Chung, L. W. K., & Nie, S. *In vivo cancer targeting and imaging with semiconductor quantum dots*. Nature Biotechnology, 2004; 22(8): 969–976. https://doi.org/10.1038/nbt994
50. Alivisatos, A. P. *The use of nanocrystals in biological detection*. Nature Biotechnology, 2004; 22(1): 47–52. https://doi.org/10.1038/nbt1018
51. Hardman, R. *A toxicologic review of quantum dots: Toxicity depends on physicochemical and environmental factors*. Environmental Health Perspectives, 2006; 114(2): 165–172. https://doi.org/10.1289/ehp.8284
52. Derfus, A. M., Chan, W. C. W., & Bhatia, S. N. *Probing the cytotoxicity of semiconductor quantum dots*. Nano Letters, 2004; 4(1): 11–18. https://doi.org/10.1021/nl0347334
53. Baker, S. N., & Baker, G. A. *Luminescent carbon nanodots: Emergent nanolights*. Angewandte Chemie International Edition, 2010; 49(38): 6726–6744. https://doi.org/10.1002/anie.200906623
54. Kairdolf, B. A., Smith, A. M., Stokes, T. H., Wang, M. D., Young, A. N., & Nie, S. *Semiconductor quantum dots for bioimaging and biodiagnostic applications*. Annual Review of Analytical Chemistry, 2013; 6: 143–162. https://doi.org/10.1146/annurev-anchem-060908-155136
55. Smith, A. M., Duan, H., Mohs, A. M., & Nie, S. *Bioconjugated quantum dots for in vivo molecular and cellular imaging*. Advanced Drug Delivery Reviews, 2008; 60(11): 1226–1240. https://doi.org/10.1016/j.addr.2008.03.015

56. Boverhof, D. R., Bramante, C. M., Butala, J. H., Clancy, S. F., Lafranconi, M., West, J., & Gordon, S. C. Comparative assessment of nanomaterial definitions and safety evaluation considerations. *Regulatory Toxicology and Pharmacology,* 2015; *73*(1): 137–150. https://doi.org/10.1016/j.yrtph.2015.06.001
57. Fadeel, B., Farcal, L., Hardy, B., Vázquez-Campos, S., Hristozov, D., Marcomini, A., Lynch, I., & Valsami-Jones, E. Advanced tools for the safety assessment of nanomaterials. *Nature Nanotechnology,* 2018; *13*(7): 537–543. https://doi.org/10.1038/s41565-018-0185-0
58. European Medicines Agency. (2020). *Reflection paper on nanotechnology-based medicinal products for human use*. European Medicines Agency. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-nanotechnology-based-medicinal-products-human-use_en.pdf
59. United States Food and Drug Administration. (2022). *Drug products, including biological products, that contain nanomaterials: Guidance for industry*. U.S. Food and Drug Administration.https://www.fda.gov/regulatory-information/search-fda-guidance documents/drug-products-including-biological-products-contain-nanomaterials-guidance-industry
60. OECD. (2022). *Important issues on risk assessment of manufactured nanomaterials*. OECD Publishing. https://www.oecd.org/chemicalsafety/nanosafety/
61. Lim, S. Y., Shen, W., & Gao, Z. Carbon quantum dots and their applications. *Chemical Society Reviews,* 2015; *44*(1): 362–381. https://doi.org/10.1039/C4CS00269E
62. Shi, Y., Wu, Y., & Zhang, J. Artificial intelligence-assisted design of nanomedicines: Current progress and future perspectives. *Advanced Drug Delivery Reviews,* 2023; *197:* 114886. https://doi.org/10.1016/j.addr.2023.114886
63. Zhao, Y., Jia, Y., Wang, H., & Chen, Y. Clinical translation of nanomedicine: Challenges and future opportunities. *Advanced Drug Delivery Reviews,* 2022; *186:* 114319. https://doi.org/10.1016/j.addr.2022.114319